News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Mynet Finans Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article provides a valuation analysis for Jyong Biotech Ltd (MENS), detailing its current stock price, market capitalization, and P/E TTM ratio. It also lists various sections of information available on the TradingKey platform, such as News & Analysis, Financials, and Stock Score, for …
This article provides an earnings forecast for Jyong Biotech Ltd (MENS), focusing on future EPS and revenue growth estimates. It includes current stock data, market capitalization, and a peer comparison with other pharmaceutical companies. The information presented is for general reference and not financial …
This article provides an overview of Jyong Biotech Ltd's (MENS) cash flow, including operating, investing, and financing cash flows. It highlights that the company generated -3.04M in operating cash flow in fiscal 2025, an increase of 16.09% year-over-year, and used 17.63M in financing activities. …
This article provides an overview of institutional holdings in Jyong Biotech Ltd (MENS), detailing the top shareholders and recent changes in their positions. Key institutional investors include Perfect Minds Co Ltd, Laxton Investments Company Ltd, and Linkage Gladden Enterprise Ltd, with Millennium Management LLC …
This article provides a revenue breakdown for Jyong Biotech Ltd (MENS), detailing its business segments and regional revenue and profit contributions. The article notes that relevant financial data for these categories has not yet been disclosed by the company. It serves as a placeholder …
This article provides access to the annual and quarterly income statements for Jyong Biotech Ltd (MENS) on TradingKey. It offers insights into the company's financial performance and operational efficiency. The statement details key financial metrics and answers frequently asked questions about interpreting income statements …
This article provides the quarterly and annual balance sheets for Jyong Biotech Ltd (MENS), allowing users to assess the company's financial health and key ratios. It details assets, liabilities, and shareholders' equity for various fiscal quarters, including specific figures for cash, total assets, and …
The article provides a detailed overview of Jyong Biotech Ltd (MENS) and explains how TradingKey generates its comprehensive stock scores. It outlines the methodology for calculating financial health, company valuation, earnings forecast, price momentum, institutional confidence, and risk management scores, emphasizing the various indicators …
Jyong Biotech, a biotechnology company focused on plant-derived therapeutics for urology, is emphasizing the significant market opportunity in Benign Prostatic Hyperplasia (BPH) and its commitment to global licensing partnerships. The company notes the rising BPH patient population, projected to reach 150-156 million by 2035, …
This article provides a technical analysis of Jyong Biotech Ltd (MENS), covering its support, resistance, indicators, and moving averages. It details various technical indicators like MACD, RSI, and KDJ, alongside moving averages (MA5 to MA200), offering buy, sell, or neutral signals. The analysis serves …
This article provides an overview of Jyong Biotech Ltd (MENS) focusing on its dividends and stock splits. It indicates that the company has distributed $0.00 in dividends over the past five years and currently shows no historical dividend data. The page also provides current …
This article provides a risk assessment for Jyong Biotech Ltd (MENS), detailing various financial risk indicators. It presents data on volatility, maximum drawdown, return-to-drawdown ratio, skewness, and liquidity. The report offers a comprehensive look at the company's financial health and its inherent investment risks.
Jyong Biotech is actively seeking global licensing partnerships for its Benign Prostatic Hyperplasia (BPH) drug candidate, Botreso (API-1), which is currently in Phase III clinical trials. The company is engaging with international pharmaceutical firms after participating in the BIO 2026 International Convention, having already …
Jyong Biotech Ltd. (NASDAQ:MENS) saw a significant drop in short interest in June, decreasing by 36.2% to 208,547 shares with a days-to-cover ratio of only 1.1 days. Analyst sentiment remains negative, with Weiss Ratings reaffirming a "sell (e+)" rating, and the stock exhibiting volatility …
Search by ticker symbol or company name and select a result to open its chart.